



ESMO 2025:

Ones to watch

Explore the headlines set to surface at ESMO 2025





ADCs make their move into early-stage disease

Drugs like Enhertu and Padcev, already headline-makers in metastatic disease, are now making waves in early-stage settings. DESTINY-Breast05, DESTINY-Breast11, and KEYNOTE-905 will hit presidential sessions, and will raise questions on safety in curable populations and how these developments align with de-escalation and ctDNA-guided strategies.




Pluvicto eyes expansion into mHSPC

With PSMAAddition results, Pluvicto aims to move from mCRPC to hormone-sensitive prostate cancer (mHSPC). Attention will focus on patient selection for radioligand therapies (RLT) amid greater competition and a younger patient population, as well as the scalability of RLT to support this additional population.



IO plus BCG; a new SOC for NMIBC?

Checkpoint inhibitors moving earlier in non-muscle invasive bladder cancer (NMIBC) could help prevent recurrence and reduce the need for radical surgery. Results from two phase III trials are coming in BCG-naïve NMIBC: POTOMAC, toplined positive (though not OS-powered), and ALBAN, still unreported. Will ESMO give a clear green light - or leave the field with mixed signals?



ctDNA guiding adjuvant IO strategy in MIBC

IMvigor011 could redefine adjuvant decision-making in MIBC. While surgery ± neoadjuvant chemotherapy remains standard, relapse rates are high – yet IMvigor010 showed no benefit for adjuvant IO in all comers. IMvigor011 suggests a smarter path forward, with DFS and OS benefits when IO is reserved for ctDNA-positive, high-risk patients.



China's oncology breakthroughs

Three China-only Phase III trials feature in ESMO's presidential lineup, highlighting China's growing influence on global oncology. With ivonescimab showing domestic results can translate internationally, these trials will be watched as a "first look" ahead of broader studies.



We're ready to discuss how the latest oncology developments could shape strategy and decisions. Meet us at ESMO 2025 - reach out to set up a conversation.



Paula Coyle



Siobhan Davies

oncology@beyondblueinsight.com

